Vistagen Therapeutics Inc.
VTGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.65M
Close$
$2.13
269.8% upside
Current Fair Value
269.8% upsideUndervalued by 269.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.65 Million |
|---|---|
| Enterprise Value | $-23,677,182.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.67 |
| Beta | 0.3 |
| Outstanding Shares | 42,234,405 |
Return
| Return on Equity | -131.67% |
|---|---|
| Return on Assets | -103.06% |
| Return on Invested Capital | -134.64% |
Valuation & Multiples
| P/E Ratio | -0.4 |
|---|---|
| PEG | -1.16 |
| Price to Sales | - |
| Price to Book Ratio | 0.58 |
| Enterprise Value to Revenue | -29.97 |
| Enterprise Value to EBIT | 0.34 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.13 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
February 12, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$364,433
Average shareholder expectationNext Earnings Call
Expected Date
June 16, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
$399,900
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0691▼ 64.55% |
|---|---|
| Total Calls | 516,800▼ 50.08% |
| Total Puts | 35,700▼ 95.17% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 34.88%▲ 2.32% |
|---|---|
| Total Invested | $8.12M▼ 8.05% |
| Investors Holding | 61▼ 3.00% |
ESG Score
No data
About VistaGen Therapeutics Inc
21 employeesVistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CN...